According to a recent FiercePharma article, Sinovac Biotech has attracted a significant investment to increase manufacturing capacity for their Covid-19 vaccine. Sino Biopharmaceutical will pay $515 million for a 15.03% stake in Sinovac Life Sciences, a subsidiary of the vaccine specialist. The money will go directly to the development, manufacturing, and production capacity of their vaccine, CoronaVac.
Sinovac Gets Investment to Double Covid Vaccine Capacity
The Chinese pharmaceutical company raised over half a billion dollars to ramp up manufacturing.
Dec 11, 2020
Recommended
Recommended
Pharmaceutical Innovations Report
Discover the latest breakthrough packaging technologies shaping the pharmaceutical sector. This report dives into cutting-edge innovations, from smart containers that enhance patient safety to eco-friendly materials poised to transform the industry’s sustainability practices. All from PACK EXPO. Learn how forward-thinking strategies are driving efficiency and redefining what’s possible in pharma packaging.
Learn More
Break out of the ordinary: see what’s new in life sciences packaging
<strong>At PACK EXPO Las Vegas, you’ll see machinery in action and new tech from 2,300 suppliers, collaborate with experts and explore transformative solutions. Join us in September to experience a breakthrough for life sciences products.</strong>
REGISTER NOW & SAVE!
